No Action Seen After Hearing On Policy Office

WASHINGTON-Congress has several options to strengthen the effectiveness of the White House science adviser and the Office of Science and Technology Policy (OSTP). But a hearing last month, more tame than some had expected, made clear that no changes are contemplated before the next president takes office. Part of the perception of weakness was attributed to the relatively low profile of the current adviser, William R. Graham; OSTP's modest budget of less than $2 million, and its small staff o

Written byTed Agres
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Part of the perception of weakness was attributed to the relatively low profile of the current adviser, William R. Graham; OSTP's modest budget of less than $2 million, and its small staff of 15 permanent and 20 temporary full-time employees. "All of us can agree that this activity is vastly under-manned," testified Edward David Jr., science adviser to President Nixon. "In fact, I would call the level of manning and budget ludicrously small."

But Graham, as the lead witness, stated that OSTP's staffing and operations were adequate. He said he would recommend a similar arrangement for the new administration. Although subcommittee members clearly favored a larger and more active OSTP, the hearing before the House Subcommittee on Science, Research and Technology was held "to put on record possible suggestions for ways to strengthen OSTP," said subcommittee aide Jim Wilson.

"From a congressional standpoint, it's hard to affect anything other than ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies